促进结肠炎症的饮食与含具核梭杆菌的结直肠癌风险相关
基于护士健康研究和卫生专业人员随访研究共124,433名参与者28年随访中951例有组织具核梭杆菌数据的结直肠癌病例,发现较高经验性饮食炎症模式(EDIP)评分与具核梭杆菌阳性结直肠肿瘤风险升高相关(最高 vs 最低三分位HR 1.63,95%CI 1.03-2.58),而与具核梭杆菌阴性肿瘤无关。
要点
- 较高EDIP评分与具核梭杆菌阳性结直肠癌风险升高相关(HR 1.63,95%CI 1.03-2.58)。
- EDIP评分与具核梭杆菌阴性结直肠癌无关(Ptrend = .44)。
- 高EDIP评分与近端具核梭杆菌阳性肿瘤相关,与近端具核梭杆菌阴性肿瘤无关(Pheterogeneity = .003)。
核心结论
- 基于EDIP评分,可能促进肠道炎症的饮食与具核梭杆菌阳性结直肠癌风险升高相关,而与不含该细菌的癌无关。
研究设计与样本
- 研究纳入护士健康研究(截至2012年6月1日)和卫生专业人员随访研究(截至2012年1月31日)的参与者,通过食物频率问卷计算EDIP评分。
- 对124,433名参与者随访28年,记录951例有组织具核梭杆菌数据的结直肠癌 incident 病例,采用多变量重复法Cox比例风险回归分析。
主要发现
- 较高EDIP评分与具核梭杆菌阳性结直肠肿瘤风险升高相关(Ptrend = .03);最高 vs 最低EDIP评分三分位者的风险比(HR)为1.63(95%CI 1.03-2.58)。
- EDIP评分与具核梭杆菌阴性肿瘤无关(Ptrend = .44)。
- 高EDIP评分与近端具核梭杆菌阳性结直肠肿瘤相关,而与近端具核梭杆菌阴性结直肠肿瘤无关(Pheterogeneity = .003)。
关键数值与推荐
- EDIP评分基于与血浆IL6、CRP和TNFRSF1B水平相关的18种食物摄入量计算。
临床怎么用
- 作者认为,饮食诱导的肠道炎症通过改变肠道微生物组参与结直肠癌发生;营养干预可能用于精准医学和癌症预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Specific nutritional components are likely to induce intestinal inflammation, which is characterized by increased levels of interleukin 6 (IL6), C-reactive protein (CRP), and tumor necrosis factor-receptor superfamily member 1B (TNFRSF1B) in the circulation and promotes colorectal carcinogenesis. The inflammatory effects of a diet can be estimated based on an empiric dietary inflammatory pattern (EDIP) score, calculated based on intake of 18 foods associated with plasma levels of IL6, CRP, and TNFRSF1B. An inflammatory environment in the colon (based on increased levels of IL6, CRP, and TNFRSF1B in peripheral blood) contributes to impairment of the mucosal barrier and altered immune cell responses, affecting the composition of the intestinal microbiota. Colonization by Fusobacterium nucleatum has been associated with the presence and features of colorectal adenocarcinoma. We investigated the association between diets that promote inflammation (based on EDIP score) and colorectal cancer subtypes classified by level of F nucleatum in the tumor microenvironment. METHODS: We calculated EDIP scores based on answers to food frequency questionnaires collected from participants in the Nurses' Health Study (through June 1, 2012) and the Health Professionals Follow-up Study (through January 31, 2012). Participants in both cohorts reported diagnoses of rectal or colon cancer in biennial questionnaires; deaths from unreported colorectal cancer cases were identified through the National Death Index and next of kin. Colorectal tumor tissues were collected from hospitals where the patients underwent tumor resection and F nucleatum DNA was quantified by a polymerase chain reaction assay. We used multivariable duplication-method Cox proportional hazard regression to assess the associations of EDIP scores with risks of colorectal cancer subclassified by F nucleatum status. RESULTS: During 28 years of follow-up evaluation of 124,433 participants, we documented 951 incident cases of colorectal carcinoma with tissue F nucleatum data. Higher EDIP scores were associated with increased risk of F nucleatum-positive colorectal tumors (Ptrend = .03); for subjects in the highest vs lowest EDIP score tertiles, the hazard ratio for F nucleatum-positive colorectal tumors was 1.63 (95% CI, 1.03-2.58). EDIP scores did not associate with F nucleatum-negative tumors (Ptrend = .44). High EDIP scores associated with proximal F nucleatum-positive colorectal tumors but not with proximal F nucleatum-negative colorectal tumors (Pheterogeneity = .003). CONCLUSIONS: Diets that may promote intestinal inflammation, based on EDIP score, are associated with increased risk of F nucleatum-positive colorectal carcinomas, but not carcinomas that do not contain these bacteria. These findings indicate that diet-induced intestinal inflammation alters the gut microbiome to contribute to colorectal carcinogenesis; nutritional interventions might be used in precision medicine and cancer prevention.
引用
- Liu L, Tabung FK, Zhang X, et al. Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol. 2018. PMID: 29702299. doi:10.1016/j.cgh.2018.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。